FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143340901> ?p ?o ?g. }

• W2143340901 endingPage "1860" @default.
• W2143340901 startingPage "1853" @default.
• W2143340901 abstract "The first analysis of our clinical trial on interest of using tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma was published in 2002 [5]. The aim of this paper is to update clinical results of 7 years of follow-up after the last treated patient. In the trial conducted between December 1993 and January 1999, patients without any detectable metastases after lymph node excision were randomly assigned to receive either TIL plus interleukin-2 (IL-2) for 2 months, or IL-2 only. The duration of the relapse-free interval was the primary objective. Eighty-eight patients were enrolled in the study. Currently, the last analysis performed in June 2006, after a median follow-up of 114.8 months, did not show change of non-significant extension of the relapse-free interval or overall survival. However, this second analysis strengthens our first hypothesis about the relationship between number of invaded lymph nodes and TIL treatment effectiveness. In the group with only one invaded lymph node, the estimated relapse rate was significantly lower (P (adjusted) = 0.0219) and the overall survival was increased (P (adjusted) = 0.0125) in the TIL+IL-2 arm compared with the IL-2 only arm. No differences between the two arms, either with regard to the duration of disease-free survival (P (adjusted) = 0.38) or overall survival (P (adjusted) = 0.43), were noted in the group with more than one invaded lymph node, whatever the number of invaded lymph nodes. Treatment was compatible with normal daily activity. This study, with a very long follow up (median of almost 10 years), postulates for the first time relationship between TIL efficiency in stage III melanoma (AJCC) and number of invaded lymph nodes, indicating that tumor burden might be a crucial factor in the production of an effective in vitro expansion of T cells specific for autologous tumor antigen, a finding which could be of value in future vaccine development for the treatment of melanoma." @default.
• W2143340901 created "2016-06-24" @default.
• W2143340901 creator A5001247907 @default.
• W2143340901 creator A5002644565 @default.
• W2143340901 creator A5004360523 @default.
• W2143340901 creator A5019952567 @default.
• W2143340901 creator A5035899929 @default.
• W2143340901 creator A5040421668 @default.
• W2143340901 creator A5044083912 @default.
• W2143340901 creator A5050918772 @default.
• W2143340901 creator A5058975539 @default.
• W2143340901 creator A5081030349 @default.
• W2143340901 creator A5090133438 @default.
• W2143340901 creator A5090537657 @default.
• W2143340901 date "2007-06-05" @default.
• W2143340901 modified "2023-10-17" @default.
• W2143340901 title "Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma" @default.
• W2143340901 cites W1544887050 @default.
• W2143340901 cites W1964465791 @default.
• W2143340901 cites W1985770829 @default.
• W2143340901 cites W1994850185 @default.
• W2143340901 cites W2004009702 @default.
• W2143340901 cites W2026639872 @default.
• W2143340901 cites W2063045004 @default.
• W2143340901 cites W2072093231 @default.
• W2143340901 cites W2084714208 @default.
• W2143340901 cites W2089828715 @default.
• W2143340901 cites W2115278843 @default.
• W2143340901 cites W2130542755 @default.
• W2143340901 cites W2148523692 @default.
• W2143340901 cites W2161585699 @default.
• W2143340901 cites W358026743 @default.
• W2143340901 doi "https://doi.org/10.1007/s00262-007-0340-1" @default.
• W2143340901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17549472" @default.
• W2143340901 hasPublicationYear "2007" @default.
• W2143340901 type Work @default.
• W2143340901 sameAs 2143340901 @default.
• W2143340901 citedByCount "48" @default.
• W2143340901 countsByYear W21433409012012 @default.
• W2143340901 countsByYear W21433409012013 @default.
• W2143340901 countsByYear W21433409012014 @default.
• W2143340901 countsByYear W21433409012015 @default.
• W2143340901 countsByYear W21433409012016 @default.
• W2143340901 countsByYear W21433409012017 @default.
• W2143340901 countsByYear W21433409012018 @default.
• W2143340901 countsByYear W21433409012020 @default.
• W2143340901 countsByYear W21433409012021 @default.
• W2143340901 countsByYear W21433409012022 @default.
• W2143340901 crossrefType "journal-article" @default.
• W2143340901 hasAuthorship W2143340901A5001247907 @default.
• W2143340901 hasAuthorship W2143340901A5002644565 @default.
• W2143340901 hasAuthorship W2143340901A5004360523 @default.
• W2143340901 hasAuthorship W2143340901A5019952567 @default.
• W2143340901 hasAuthorship W2143340901A5035899929 @default.
• W2143340901 hasAuthorship W2143340901A5040421668 @default.
• W2143340901 hasAuthorship W2143340901A5044083912 @default.
• W2143340901 hasAuthorship W2143340901A5050918772 @default.
• W2143340901 hasAuthorship W2143340901A5058975539 @default.
• W2143340901 hasAuthorship W2143340901A5081030349 @default.
• W2143340901 hasAuthorship W2143340901A5090133438 @default.
• W2143340901 hasAuthorship W2143340901A5090537657 @default.
• W2143340901 hasBestOaLocation W21433409011 @default.
• W2143340901 hasConcept C126322002 @default.
• W2143340901 hasConcept C141071460 @default.
• W2143340901 hasConcept C142724271 @default.
• W2143340901 hasConcept C143998085 @default.
• W2143340901 hasConcept C146357865 @default.
• W2143340901 hasConcept C151730666 @default.
• W2143340901 hasConcept C2776694085 @default.
• W2143340901 hasConcept C2777658100 @default.
• W2143340901 hasConcept C2777863537 @default.
• W2143340901 hasConcept C2777982462 @default.
• W2143340901 hasConcept C2779720271 @default.
• W2143340901 hasConcept C2780849966 @default.
• W2143340901 hasConcept C502942594 @default.
• W2143340901 hasConcept C71924100 @default.
• W2143340901 hasConcept C86803240 @default.
• W2143340901 hasConceptScore W2143340901C126322002 @default.
• W2143340901 hasConceptScore W2143340901C141071460 @default.
• W2143340901 hasConceptScore W2143340901C142724271 @default.
• W2143340901 hasConceptScore W2143340901C143998085 @default.
• W2143340901 hasConceptScore W2143340901C146357865 @default.
• W2143340901 hasConceptScore W2143340901C151730666 @default.
• W2143340901 hasConceptScore W2143340901C2776694085 @default.
• W2143340901 hasConceptScore W2143340901C2777658100 @default.
• W2143340901 hasConceptScore W2143340901C2777863537 @default.
• W2143340901 hasConceptScore W2143340901C2777982462 @default.
• W2143340901 hasConceptScore W2143340901C2779720271 @default.
• W2143340901 hasConceptScore W2143340901C2780849966 @default.
• W2143340901 hasConceptScore W2143340901C502942594 @default.
• W2143340901 hasConceptScore W2143340901C71924100 @default.
• W2143340901 hasConceptScore W2143340901C86803240 @default.
• W2143340901 hasIssue "11" @default.
• W2143340901 hasLocation W21433409011 @default.
• W2143340901 hasLocation W21433409012 @default.
• W2143340901 hasOpenAccess W2143340901 @default.
• W2143340901 hasPrimaryLocation W21433409011 @default.
• W2143340901 hasRelatedWork W1966798989 @default.

• next